Eli Lilly and Company (LLY)
Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker's blood-cancer portfolio.
Eli Lilly: A Heavyweight Battle Isn't Won In Round 1
Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo versus Novo Nordisk's oral Wegovy. LLY's long-term advantage lies in small molecule manufacturing economics, Zepbound switcher potential, and durable gross margin prospects. My updated DCF analysis values LLY at $970.83/share, about 10% above current levels, supporting a continued 'Buy' rating.
Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake
Shares of Eli Lilly came under pressure on Friday after early prescription data for its newly launched weight-loss pill suggested a slower rollout compared with rival Novo Nordisk's competing product. According to data from healthcare analytics firm IQVIA, Lilly's Foundayo recorded 3,707 prescriptions in the US during its second week on the market, up from 1,390 in its debut week, which covered only two days.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Eli Lilly (LLY) concluded the recent trading session at $903.02, signifying a -1.83% move from its prior day's close.
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.
Eli Lilly: We Haven't Reached Its Peak Yet (Rating Upgrade)
Eli Lilly: We Haven't Reached Its Peak Yet (Rating Upgrade)
Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind
Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026. LLY's acquisition of Kelonia and Orna Therapeutics positions it at the forefront of in vivo CAR-T therapies, targeting major market expansion. The weight loss franchise drives 56% of LLY revenue but faces pricing, legal, and regulatory risks; monitoring volume vs. price dynamics is critical.
Eli Lilly expands genetic medicine capabilities with Kelonia Therapeutics acquisition
Eli Lilly and Co (NYSE:LLY) has agreed to acquire private clinical-stage biotechnology firm Kelonia Therapeutics in a deal aimed at expanding its capabilities in genetic medicines, the companies announced on Monday. The transaction centers on Kelonia's in vivo gene delivery platform, known as iGPS, which uses engineered lentiviral-based particles designed to modify T-cells inside the body.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday.
Eli Lilly Nears Deal for Cancer Biotech
Deal for Kelonia Therapeutics could come as soon as Monday.
